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Yun Jiaoa, Yuchen Doua, Georgina Lockwooda,b, Amar Pania and Richard Jay Smeynea,∗
aDepartment of Developmental Neurobiology, St. Jude Children’s Research Hospital, Memphis, TN, USA
bDepartment of Biochemistry, University of Bath, Bath, UK
Abstract.
Background: MPTP and paraquat are two compounds that have been used to model Parkinson’s disease in mice. Previous
studies in two non-traditional strains of mice have shown that a single dose of MPTP can induce changes in body temperature,
while the effects of paraquat have not been examined. Examination of body temperature is important since small fluctuations
in an animal’s core temperature can significantly affect drug metabolism, and if significant enough can even culminate in an
animal’s death.
Objective: To determine how external heating can alter the survival of C57BL/6J mice following MPTP administration.
Methods: In this study, we examine the effects of MPTP (4 × 20 mg/kg, 2 hours apart) and paraquat (2 × 10 mg/kg/week for 3
weeks) on core temperature of C57BL/6J mice. Correlations of purine and catecholamine levels were also done in mice treated
with MPTP.
Results: We find that MPTP induces a significant hypothermia in C57BL/6J mice that reduces their core temperature below the
limit of fatal hypothermia. Unlike MPTP, paraquat did not induce a significant hypothermia. Placement of animals on heating
pads significantly abrogates the loss of core temperature. In both heated and non-heated conditions, mice treated with MPTP
showed a significant depletion of ATP within 2 hours of administration in both striatum and SN that started to recover 2 hours
after MPTP administration was complete. Striatal DA and DOPAC are significantly reduced starting 4–6 hours after MPTP.
Conclusions: The fatal hypothermic effects of MPTP can be abrogated through use of external heating.
Keywords: Mouse strain, MPTP, paraquat, temperature, fatal hypothermic temperature
INTRODUCTION
Animal models of Parkinson’s disease (PD) fall into
two broad categories. These are: 1) models induced by
exogenous administration of substances, i.e. 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridineorparaquat,and2)
models generated through manipulation of the genome.
In the former, substances are administered peripherally
and through various mechanisms are metabolized until
they effect a neurodegenerative action.
∗Correspondence to: Richard Jay Smeyne, Ph.D., Department
of Developmental Neurobiology, Memphis, TN 38105, USA.
Tel.: +1 901 595 2830; Fax: +1 901 595 3143; E-mail:
Richard.Smeyne@STJUDE.ORG.
In terms of exogenous models, the most widely used
compound for induction of dopamine insufficiency to
mimic that seen in PD is the systemic administration
of the tertiary amine, 1-methyl–4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP). This agent was identified
following the study of young adult heroin addicts
who unknowingly injected the synthetic heroin, 1-
methyl-4-phenyl-4-propionoxypiperidine (MPPP) that
contained the contaminant, MPTP; after which they
presented with symptoms indistinguishable from those
of later stage PD patients [1, 2].
Another compound that has been used to induce
experimental parkinsonism is 1,1′ di methyl-4,4′-
bipyridium dichloride (paraquat, PQ). PQ is a
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commonly used non-selective herbicide that has been
epidemiological linked to Parkinson’s disease [3, 4].
Experimentally, administration of PQ by systemic or
direct injection into the CNS induces a relatively spe-
cific lesion in the SNpc that results in a small but
significant dopaminergic neuron loss [5–9] (although
note [10]). The relative small loss of DA neurons over
a more protracted period of time appears to allow for
plasticity in the system such that despite neuron loss
in the SN, there is no apparent loss of dopamine in the
striatum [11–13].
Paraquat can cross the blood brain barrier [14], but
unlike MPTP, acts as a direct redox cycling agent that
reduces molecular oxygen to its cationic radical that
then further reduces molecular oxygen to its superox-
ide radical [15–17]. In addition to its direct effect on
membrane phospholipids, PQ also actively transports
into neurons via neutral amino acid transporters [18]
where is damages mitochondria leading to secondary
oxidative stress [19, 20] and eventual cell death through
a BAK-dependent mechanism [21].
Since MPTP and PQ are generally administered via
the periphery, either through direct injection or dietary
means, one must also be aware of peripheral effects
that could synergize with the CNS effects. Previous
reports have shown that MPTP and/or PQ can induce
cardiac [22, 23], lung [24] and kidney [25, 26] toxicity
and alterations in muscle function [27]. In addition to
these agent’s abilities to damage organ systems, we,
and other have observed that peripheral administration
of these chemicals appears to induce changes in the
animal’s core body temperature [28–30].
Maintenance of body temperature is a combinato-
rial function of heat generation and heat loss; and
small fluctuations in animal core temperature can have
significant effects in physiological systems (cardiovas-
cular, endocrine, nervous system) that can culminate in
an animal’s death [31]; each of which has been reported
with MPTP [32] and paraquat [24].
In this paper, we examine the effect of administering
MPTP (acute administration of 4 × 20 mg/kg spaced
two hours apart) and paraquat (2 × 10 mg/kg/week × 3
weeks) on the core temperature in C57BL/6J mice.
We find that acute MPTP treatment induces a rapid
and lasting hypothermia that can be abrogated by
increasing the environmental ambient temperature.
The loss of body temperature correlates with a sig-
nificant loss of ATP and dopamine in the striatum
and ATP in the substantia nigra. Paraquat, like MPTP,
also induces a transient hypothermia; however, unlike
MPTP, animal’s treated with paraquat return to normal
temperature soon after administration.
MATERIALS AND METHODS
Ethics statement
All of the experimental procedures in the animals
were performed in accordance with the NIH Guide
for the Care and Use of Laboratory Animals and all
protocols, were approved by the St Jude Children’s
Research Hospital IACUC (protocol 364). Experi-
ments were carried out in accordance with The Code of
Ethics of the World Medical Association (Declaration
of Helsinki) for animal experiments.
Animals
16–20 week old male C57BL/6J mice (Jackson
Labs, Bar Harbor, ME) mice were used in this study.
Mice were housed 5 to a polycarbonate cage within
the vivarium at St. Jude Children’s Research Hospital
and were maintained on a 12:12 hour light:dark cycle.
The animals were provided with corn cob bedding, ad
libitum food (LabDiet 5013, Purina) and water.
Measurement of cage temperature
To determine the temperature of the animal’s envi-
ronment, iButton® Temperature Data Loggers (QA
Supplies, LLC, Norfolk, VA) were placed in each cage
and temperature was determined at 1 hour intervals.
Over the course of the experimental procedure, the
ambient temperature of the cages in the holding room
was 23.2◦C (73.8 ± 0.10 ◦F), never fluctuating more
than ± 5%. Twenty-four hours prior to administration
of MPTP or paraquat, mice were transferred from their
holding room to caging maintained within a vented
fume hood that had an empirically determined ambi-
ent temperature of 21.2 ± 0.1◦C (70.2◦F), which is
within the optimal housing range for mice [33]. One
half of the cages in the vented hood were maintained
on heating pads set to “medium” which were empiri-
cally determined to be 35.1 ± 1.0◦C (95.2 ± 2.0◦F).
When cages were placed on the heating pads the ambi-
ent cage temperature was empirically determined to be
24.6 ± 0.3 ◦C (76.3 ± 0.6 ◦F).
The other one-half of the mice were housed in cages
seated on heating pads that were turned off. Mice were
allowed 24 hours of acclimation in this new environ-
ment prior to administration of MPTP or paraquat.
MPTP treatment
C57BL/6J mice were administered either vehi-
cle [0.9% sterile saline (Sal)] or MPTP (Catalog
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# M103, Sigma, St. Louis, MO) using the acute pro-
tocol (4 × 20 mg/kg MPTP-HCl ip injections at 2-h
intervals, equivalent to 16.8 mg/kg free base) [34].
One-half of the mice injected with MPTP were main-
tained on heating pads and one-half of the mice were
housed in cages seated on heating pads that were
turned off. We have empirically observed that mice
become hypokinetic and exhibit piloerection and wet
dog shakes following administration of MPTP. Addi-
tionally, it has also been well documented that certain
strains of mice, including C57BL/6J, can suffer from a
non-predictable death (cause unknown, although spec-
ulated to be cardiac in nature) within 24 hours of its
administration [35]. However, since there is no clear
biomarker available that will allow one to determine
if any particular mouse will succumb to MPTP toxic-
ity, and almost all mice injected using the acute MPTP
paradigm appear (at some time during the 8 hours of the
injection period) moribund, an a priori determination
of a humane endpoint during the injection protocol for
euthanasia could not be made. However, prior to the
start of the procedure, the protocol called for humane
sacrifice within 24 hours of the final injection.
Paraquat treatment
1,1′ di methyl-4,4′-bipyridium dichloride (paraquat,
PQ) (Catalog #36541 Sigma-St. Louis, MO) was dis-
solved in sterile saline to a final concentration of
20 mg/ml. Each animal was given a total of 60 mg/kg
of PQ, using a dosage regimen of 10 mg/kg × 2 per
week for 3 weeks. One-half of the mice injected with
PQ were maintained on heating pads and the other
one-half of the mice were housed in cages seated on
heating pads that were turned off. Like, MPTP, an a
priori determination of a humane endpoint during the
injection protocol for euthanasia could not be made.
However, prior to the start of the procedure, the proto-
col called for humane sacrifice within 24 hours of the
final injection.
Measurement of core temperature
Seven days prior to treatment with MPTP or
paraquat, mice were anesthetized with inhaled isoflu-
orane. Once deep tendon reflexes were absent, a 2
cm2 area of fur was removed from the intrascapular
region and the exposed skin was cleaned with alter-
nating iodine and 70% ethanol. The skin was then
incised and a 10 g syringe preloaded with a temperature
transponder with a programmable Radio Frequency
Identification (RFID) signal (IPTT-300, BioMedic
Data Systems, Inc., Seaford, DE) was placed subcu-
taneously and the transponder was expelled. Once the
transponder was in place, the needle was removed and
the skin was closed using a drop of n-butyl cyanoacry-
late glue (Vet Bond®, Fisher Scientific). Once the glue
had set, the mouse was allowed to recover from the
isofluorane anesthesia and placed into their home cage.
Core temperatures of the C57BL/6J mice were
measured using a hand held reader (DAS-7066/7r,
BioMedic Data Systems, Inc., Seaford, DE). For the
MPTP study, animals were checked and tempera-
tures were taken at baseline and 15, 30, and 60 and
120 minutes after each MPTP injection with an addi-
tional measurement of 180 and 240 minutes following
the final (4th) injection (total of 600 minutes). For
paraquat, animals were checked and temperatures were
taken at baseline, 15, 30, 60, 120 and 24 hours after
each injection through out the entire 3-week injection
period.
Determination of purine and catecholamine levels
in striatum and substantia nigra
At Time 0, 15 minutes after each injection of MPTP
and 2 hours following the last injection of MPTP,
C57BL/6J mice were rapidly decapitated. Brains were
rapidly removed and placed in a brain matrix (Model
BS-AL-5000C, Braintree Scientific, Braintree. MA)
and sliced into 2 mm thick sections and placed on
an ice-cooled plate. Striatum and substantia nigra
were dissected using the following coordinates: SN
(Bregma: −2.00- −4.00), striatum (Bregma: +0.00-
+2.00 mm) [36]. HPLC-ECD was used to quantitate
the levels of purines (adenosine (ADO), ATP, ADP
and AMP) and catecholamines (dopamine (DA) and its
metabolites (HVA and DOPAC), as previous described
[37, 38]. Following chromatography, the signal from
the electrochemical detector was recorded using a
model SS420x integration device (Scientific Software
Inc) and the retention time of each of the analytes
were empirically determined. For both purines and cat-
echolamines, a 4-point concentration curve (12.5, 25,
50 and 100 ng/ml) of external standards (Sigma) was
generated and concentrations in tissues were quantified
by comparing the peak areas of the sample chro-
matograms with the external standard chromatograms.
Statistics
Differences in mean core temperatures, as well as
purine and catecholamine concentrations were ana-
lyzed by ANOVA using PRIZM software (GraphPad
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Software). If overall significance was found, individual
comparisons were performed using Neumann-Keuls
post-hoc comparisons.
RESULTS
Effect of external heat on animal environment
The ambient cage temperature in the procedure
room at SJCRH that were not provided access to an
external heat source was empirically determined to be
20.1 ± 0.3◦C (68.2 ± 0.6 F). The ambient cage temper-
ature in the procedure room at SJCRH that were pro-
vided access to an external heat source (35.1 ± 1.0 ◦C,
95.2 ± 2.0◦F) was empirically determined to be
24.6 ± 0.3 ◦C (76.3 ± 0.6 ◦F).
Effect of MPTP on core temperature
10 male C57BL/6J mice were administered 4
ip injections of MPTP (20 mg/kg) spaced 2 hours
apart, while 10 C57BL/6J male C57BL/6J control
animals were placed on heating pads and injected
ip with 0.1 ml sterile 0.9% saline. Two tempera-
ture conditions were examined: those housed on
heating pads (heat) and those housed at ambient tem-
perature (no heat). Both groups had similar core
temperatures at the start of the experiment (C57BL/6J
with heat = 38.5 ± 0.1◦C (101.2 ± 0.29 ◦F); C57BL/6J
without heat = 38.3 ± 0.1◦C (100.8 ± 0.21 ◦F), and
(Table 1 and Fig. 1).
C57BL/6J mice housed in non-heated conditions
(n = 5) that were administered an ip injection of MPTP
showed a rapid 4.5% (35.7◦C, 96.3◦F) drop in core
temperature that progressed to a loss of 10% (32.8◦C,
90.9◦F) at the conclusion of the first 2 hour inter-
injection period. Following the second injection-at the
120-minute mark- the core temperature continued to
fall, so that at the end of the 2nd inter-injection period,
the core temperature of the C57BL/6J mice with-
out parental heat support fell another 7.0% (29.2◦C,
84.6◦F). After the third injection-at the 360 minute
mark- the core temperature continued to fall another
5.0% (26.9◦C, 80.4◦F), while 4 hours after the 4th
injection, the core temperature of these C57BL6J mice
fell another 10% (20.4◦C, 68.8◦F) for a total loss
of 31% over the whole injection period. Twenty-four
hours following the start of the injection, all of the mice
(5 out of 5) that did not have additional access to an
external heat source had died, likely due to the fact
that they had surpassed the point of Fatal Hypothermic
Temperature [31].
A second group of 5 male C57BL/6J mice were
housed on heating pads and given the same dosing reg-
imen of MPTP. These mice showed a rapid 2.8% drop
in core temperature (36.9◦C, 98.4◦F) that progressed
to a loss of 5.5% (35.3◦C, 95.5◦F) at the conclusion
of the first 2-hour inter-injection period. Following the
second injection-at the 120 minute mark- the core tem-
perature continued a gradual fall, so that at the end of
the 2nd inter-injection period, the core temperature of
the C57BL/6J mice that had parental heat support fell
another 10.8% (29.6◦C, 85.3◦F). After the third injec-
tion, the behavior of the core temperatures changed.
Instead of continuing to fall, the core temperature of
the mice rose by 3% (31.0◦C, 87.8 ◦F), while 4 hours
after the 4th injection, the core temperature continued
to recovered (32.2◦C, 90.0◦F) so that the total loss of
body temperature was only 17% over the whole injec-
tion period and by 6 hours the total loss was only 1.1%.
Unlike the mice that did not have access to an external
heat source, only 1 out of 5 of these animals died.
To determine the effect of animal handling and ip
injections on body temperature with (n = 5) and with-
out (n = 5) supplementary heat, C57BL/6J mice were
administered 4 ip injections of 0.9% saline using the
same average injection volume as the MPTP-treated
mice (0.1 ml/injection). As can be seen in Fig. 1 and
Table 1, the core temperature variance of these mice
Fig. 1. Effect of MPTP on Core Temperature in C57BL/6J mice. In
C57BL/6J mice administered acute MPTP-HCl (4 × 20 mg/kg, each
injection spaced 2 hours apart) without heat support (black lines),
there is a rapid hypothermic effect that is progressive throughout the
entire measurement period of 600 minutes. When heat support is pro-
vided, MPTP is still hypothermic, although the effect is significantly
modified (blue lines). Administration of saline with supplemental
heat (red) or without supplemental heat (green) has no effect on the
core temperature of C57BL/6J mice.
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Table 1
Effect of Heat Supplementation on Core Temperature (◦C) following MPTP in the Male C57BL/6J Mouse
Injection Cumulative C57BL/6J+ C57BL/6J+ C57BL/6J+ C57BL/6J+ Statistics
time minutes MPTP+No Heat MPTP+Heat saline+No Heat saline+Heat
Baseline (0 minutes) 0 38.3 ± 0.1 38.5 ± 0.2 37.9 ± 0.2 37.2 ± 0.2 NS
Injection 1–15 minutes 15 35.7 ± 0.3 36.9 ± 0.2 38.2 ± 0.2 38.3 ± 0.2 1, 2, 3,4, 5
Injection 1–30 minutes 30 35.2 ± 0.3 37.1 ± 0.2 38.2 ± 0.1 38.2 ± 0.1 1,2,3
Injection 1–60 minutes 60 33.1 ± 0.6 36.4 ± 0.3 37.8 ± 0.2 38.1 ± 0.3 1,2,3
Injection 1–120 minutes 120 32.7 ± 0.7 35.3 ± 0.5 37.2 ± 0.1 37.9 ± 0.3 1,2,3
Injection 2–15 minutes 135 32.1 ± 0.7 36.2 ± 0.4 37.7 ± 0.2 37.7 ± 0.4 1,2,3
Injection 2–30 minutes 150 32.3 ± 0.5 36.1 ± 0.3 37.8 ± 0.2 37.1 ± 0.3 1,2,3
Injection 2–60 minutes 180 30.7 ± 0.6 32.1 ± 0.8 37.2 ± 0.2 36.4 ± 0.3 2,3,4,5
Injection 2–120 minutes 240 29.4 ± 1.0 29.6 ± 0.6 36.5 ± 0.2 37.8 ± 0.2 2,3,4,5
Injection 3–15 minutes 255 29.0 ± 1.2 30.7 ± 0.8 37.4 ± 0.2 37.0 ± 0.2 2,3,4,5
Injection 3–30 minutes 270 28.8 ± 1.2 31.3 ± 0.8 37.3 ± 0.1 36.0 ± 0.5 1,2,4,5
Injection 3–60 minutes 300 28.5 ± 0.9 32.4 ± 0.5 36.2 ± 0.3 35.7 ± 0.3 1,2,3,4,5
Injection 3–120 minutes 360 26.9 ± 1.0 31.0 ± 0.7 36.0 ± 0.2 37.1 ± 0.2 1,2,3,4,5
Injection 4–15 minutes 375 26.1 ± 0.9 32.2 ± 0.9 37.5 ± 0.2 37.1 ± 0.3 1,2,3,4,5
Injection 4–30 minutes 390 25.6 ± 1.0 32.1 ± 0.6 36.9 ± 0.1 37.0 ± 0.3 1,2,3,4,5
Injection 4–60 minutes 420 24.6 ± 0.8 32.3 ± 0.6 35.9 ± 0.1 36.1 ± 0.1 1,2,3,4,5
Injection 4–120 minutes 480 22.4 ± 1.0 32.2 ± 1.0 35.9 ± 0.1 35.8 ± 0.2 1,2,3
Injection 4–540 minutes 540 21.1 ± 0.8 30.7 ± 1.3 35.7 ± 0.4 35.5 ± 0.0 1,2,3
Injection 4–600 minutes 600 20.5 ± 1.0 38.5 ± 1.4 35.7 ± 0.1 37.5 ± 0.3 2,3,4,5
1: p≤ 0.05, C57BL/6J MPTP+no heat vs C57BL/6J MPTP+Heat. 2: p≤ 0.05, C57BL/6J MPTP+no heat vs C57BL/6J saline+no heat. 3:
p≤ 0.05, C57BL/6J+MPTP+no heat vs C57BL/6J Saline+Heat. 4: p≤ 0.05, C57BL/6J MPTP Heat vs C57BL/6J saline+no heat. 5: p≤ 0.05,
C57BL/6J MPTP Heat vs C57 Saline Heat. 6: p≤ 0.05, C57BL/6J saline+no heat vs C57BL/6J Saline+Heat.
never varied more than 4% and at the end of the period
had risen on average only 0.5%. Twenty-four hours
after administration of ip saline, none of these male
C57BL/6J mice had died.
Effect of paraquat on core temperature
10 male C57BL/6J mice were administered a
total of 6 ip injections of paraquat (10 mg/kg)
over a period of 3 weeks, with 2 injections/week
spaced 2 days apart. A second group of 10 male
C57BL/6J control animals were injected ip with
0.1 ml sterile 0.9% saline using the same injection
calendar. Two temperature conditions were exam-
ined: those housed on heating pads (heat) and
those housed at ambient temperature (no heat). Each
groups had similar core temperatures at the start of
the experiment (C57BL/6J with heat = 99.7 ± 0.3 F
(n = 5); C57BL/6J without heat = 100.5 ± 0.2 F (n = 5),
C57BL/6J+PQ+No Heat = 100.4 ± /2 (n = 5), and
C57BL/6J + PQ + Heat = 99.6 ± 0.3 (n = 5)) (Table 2
and Fig. 2).
Unlike C57BL/6J male mice administered MPTP,
the first 4 injections of paraquat (weeks 1 and 2) did
not induced hypothermia, but rather there seemed to
be a small 1-2◦C increase in core temperature. How-
ever, as can be seen in Table 2 and Fig. 2, this transient
hyperthermia was observed in both mice that received
PQ or saline; suggesting that this change was due to
stress induced by the injection procedure and not the
PQ itself. In the third week of injections, we did note
that mice receiving PQ had a reduced core tempera-
ture compared to those receiving saline. Interestingly,
animals given PQ without external heat support had
a higher core body temperature 24 hours after PQ
(Despite the lack of a significant change in body core
temperature, we did observe that mice that were housed
in cages with an external heat source did have lower
core temperatures than those housed in cages without
an external heat source (Fig. 2, red lines compared to
green lines).
Effect of MPTP on purine levels in the striatum
and substantia nigra
Given that we observed a significant decrease
in core temperature in C57BL.6J mice following
MPTP, we examined the concentration of purines,
including adenosine (ADO), adenosine triphosphate
(ATP), adenosine diphosphate (ADP) and adenosine
monophosphate (AMP) in two regions of the brain
(striatum and substantia nigra) that are known to be
affected by this toxin.
Following MPTP, there was no change in adenosine,
ADP or AMP in the striatum in animals with and with-
out external heat (Fig. 3). We did find a significant drop
in striatal ATP 15 minutes after the 2nd injection of
MPTP (135 minutes after the 1st injection) that lasted
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Table 2
Effect of Heat Supplementation on Core Temperature (◦C) following Paraquat in the C57BL/6J Mouse
C57BL/6J+ C57BL/6J+ C57BL/6J+ C57BL/6J+ Statistics
PQ+No Heat PQ+Heat saline+Heat saline+No Heat
Baseline (injection 1) 38.0 ± 0.1 37.4 ± 0.2 37.6 ± 0.3 38.5 ± 0.3 NS
15 minutes 37.7 ± 0.2 37.9 ± 0.1 38.0 ± 0.4 38.7 ± 0.3 NS
30 minutes 37.1 ± 0.2 37.1 ± 0.1 37.9 ± 0.3 38.3 ± 0.2 3,5
60 minutes 37.4 ± 03 37.4 ± 0.1 37.5 ± 0.3 37.5 ± 0.3 NS
120 minutes 37.1 ± 0.4 36.4 ± 0.3 37.0 ± 0.6 37.8 ± 0.3 NS
24 hours 37.3 ± 0.1 37.1 ± 0.2 36.3 ± 0.4 38.3 ± 0.2 2,3,5,6
Baseline (injection 2) 36.7 ± 0.3 36.7 ± 0.4 36.6 ± 0.2 38.6 ± 0.3 3,6
15 minutes 38.1 ± 0.2 37.8 ± 0.1 37.7 ± 0.3 38.7 ± 0.3 NS
30 minutes 37.8 ± 0.2 37.3 ± 0.1 37.4 ± 0.1 38.4 ± 0.3 3,6
60 minutes 37.2 ± 02 36.6 ± 0.1 36.9 ± 0.2 37.9 ± 0.4 5
120 minutes 36.3 ± 0.2 35.6 ± 0.2 37.1 ± 0.2 37.8 ± 0.3 3,4,5
24 hours 36.7 ± 0.2 35.9 ± 0.2 36.6 ± 0.3 38.0 ± 0.2 3,5,6
Baseline (injection 3) 36.7 ± 0.3 37.1 ± 0.4 36.3 ± 0.4 36.8 ± 0.4 NS
15 minutes 37.9 ± 0.3 38.2 ± 0.1 38.4 ± 0.2 38.6 ± 0.2 NS
30 minutes 37.8 ± 0.3 37.3 ± 0.1 38.2 ± 0.1 38.5 ± 0.3 5
60 minutes 37.1 ± 0.3 36.8 ± 0.1 36.8 ± 0.1 37.7 ± 0.3 NS
120 minutes 37.0 ± 0.2 36.0 ± 0.1 36.0 ± 0.1 37.3 ± 0.2 1,2,5,6
24 hours 36.1 ± 0.8 37.2 ± 0.2 37.0 ± 0.2 37.9 ± 0.1 NS
Baseline (injection 4) 37.0 ± 0.2 37.1 ± 0.2 36.6 ± 0.2 37.6 ± 0.3 NS
15 minutes 38.2 ± 0.4 38.2 ± 0.1 37.8 ± 0.2 38.8 ± 0.2 6
30 minutes 38.0 ± 0.2 37.5 ± 0.3 37.2 ± 0.1 38.4 ± 0.2 5,6
60 minutes 37.6 ± 0.2 36.8 ± 0.1 36.9 ± 0.3 37.4 ± 0.2 NS
120 minutes 37.0 ± 0.6 36.2 ± 0.4 36.1 ± 0.2 37.2 ± 0.2 NS
24 hours 36.4 ± 0.2 36.0 ± 0.5 35.3 ± 0.2 37.1 ± 0.3 6
Baseline (injection 5) 37.5 ± 0.3 36.6 ± 0.9 36.3 ± 0.4 37.3 ± 0.4 NS
15 minutes 37.9 ± 0.6 36.6 ± 0.9 37.8 ± 0.2 38.8 ± 0.2 NS
30 minutes 37.9 ± 0.6 36.4 ± 0.7 37.2 ± 0.1 38.1 ± 0.2 NS
60 minutes 37.2 ± 0.4 36.0 ± 0.6 36.3 ± 0.2 37.5 ± 0.2 NS
120 minutes 36.9 ± 0.2 35.7 ± 0.3 36.1 ± 0.2 36.6 ± 0.2 1
24 hours 37.2 ± 0.6 35.3 ± 1.0 35.0 ± 0.1 36.8 ± 0.2 NS
Baseline (injection 6) 36.8 ± 0.4 35.5 ± 1.6 36.1 ± 0.1 37.5 ± 0.2
15 minutes 38.0 ± 0.4 35.3 ± 1.8 37.8 ± 0.1 38.9 ± 0.2
30 minutes 37.9 ± 0.3 35.2 ± 1.3 37.5 ± 0.3 38.5 ± 0.2
60 minutes 37.6 ± 0.3 35.7 ± 1.5 36.7 ± 0.3 37.5 ± 0.3
120 minutes 37.7 ± 0.4 35.7 ± 0.9 36.0 ± 0.3 37.5 ± 0.3
24 hours 37.0 ± 00 33.9 ± 2.4 35.3 ± 0.2 36.8 ± 0.2
1: p≤ 0.05, C57BL/6J PQ+no heat vs C57BL/6J PQ+Heat. 2: p≤ 0.05, C57BL/6J PQ+no heat vs C57BL/6J saline+no heat. 3: p≤ 0.05,
C57BL/6J+PQ+no heat vs C57BL/6J Saline+Heat. 4: p≤ 0.05, C57BL/6J PQ Heat vs C57BL/6J saline+no heat. 5: p≤ 0.05, C57BL/6J PQ
Heat vs C57 Saline Heat. 6: p≤ 0.05, C57BL/6J saline+no heat vs C57BL/6J Saline+Heat.
until 2 hours after the final injection of MPTP, when
ATP levels start to recover. In the SN, we observed
a similar pattern of purine effect (no loss of ADO or
ADP, significant loss of ATP, Fig. 4).
Examination of acute MPTP effects on dopamine,
DOPAC and HVA in striatum revealed a significant
loss of DA, 15 minutes after the 2nd injection (135
minutes after MPTP was first administered) in animals
that had external heat while animals not exposed to an
external heat source first showed significant changes
after the 3rd injection (195 minutes after the initial
injection of MPTP) (Fig. 5). A similar pattern of change
was observed in the measurement of DOPAC, while
significant effects on HVA were only noted after the
4th injection of MPTP. (Fig. 5). Although changes in
DA were noted as early as 15 minutes after the second
injection of MPTP, changes in DA turnover, calculated
as (DOPAC+HVA)/DA were only observed in animals
provided an external heat source starting 15 minutes
after the 4th injection of MPTP (Fig. 5).
DISCUSSION
In this study we examined the effect of two chem-
icals, MPTP and paraquat, that have been used to
induce experimental parkinsonism on core body tem-
perature in C57BL/6J mice. We find that ip injection of
MPTP has a rapid and significant hypothermic effect
on body temperature that ultimately can prove fatal
if no external heat source is supplied to mitigate this
change. Unlike MPTP, we do not observe these large
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Fig. 2. Effect of Paraquat on Core Temperature in C57BL/6J mice. Paraquat (2 injections of 10 mg/kg PQ/week spaced 48 hours apart for 3
weeks) administered to C57BL/6J mice has no significant effect on the core temperature of mice throughout the entire injection period. One
does note, however, a slight hyperthermia that is observed 15 minutes after administration of paraquat (increase of 3%) starting after the 2nd
paraquat injection that recedes within 30 minutes of administration.
hypothermic effects following ip administration of
paraquat.
Previous studies that have examined body temper-
ature following one injection of high doses of MPTP
have shown this compound induces transient hyper-
thermia followed by a profound hypothermia in both
MPTP-sensitive ddY [39] and MPTP-resistant CD-1
mice, while C57BL/6N mice only showed a hypother-
mic response [28, 40]. A similar response was seen
following administration of MPP+, with the caveat
that this also induced hyperthermia in C57BL/6N mice
[28, 40]. This suggests changes in body temperature
are independent of the central dopaminergic effects
of MPTP since MPP+, the neurotoxic metabolite of
MPTP cannot cross the blood-brain-barrier [41]. In this
study, we examined the core temperature of another
strain of mouse (C57BL/6J) widely used in MPTP and
other models of Parkinson’s disease [42]. Since the
neurotoxic effects of this compound are only seen with
repeated administration, we determined body temper-
ature for 10 hours, a period that spans the entire
MPTP administration period in our “acute” admin-
istration protocol [43]. In this study, we find that
repeated injection of MPTP induces a 31% loss of
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Fig. 3. Effect of MPTP on purine levels in the striatum. Intraperitoneal administration of 4 injections of 20 mg/kg MPTP spaced 2 hours apart
does not alter adenosine, ADP or AMP levels. Starting 15 minutes after the 2nd injection of MPTP (135 minutes after the first injection), there
is a significant loss of ATP that is maintained until 2 hrs after the last injection, when this purine begins to recover to baseline levels. The
MPTP-induced changes in ATP are not affected by the addition of an external heat source. ∗p≤ 0.05 compared to no heat controls; $p≤ 0.05
compared to heat controls.
core body temperature. This hypothermia is slightly
more profound that other studies that have examined
this variable. Satoh et al. [39] used several concen-
trations of MPTP in ddY mice and showed no more
than a 5% loss of core temperature. Freyaldenhoven
et al. [28] using single injections of 50 mg/kg MPTP
or 12.5 mg/kg MPP+ reported a maximum loss of 28%
in body temperature in 6 month C57BL/6N and a 17%
loss in CD-1 mice given MPTP. What is interesting is
that it appears that MPP+ is the critical mediator of tem-
perature change since mice pretreated with Deprenyl,
a MAO-B inhibitor that inhibits conversion of MPTP
to MPP+ significantly reduces the hypothermia
[28].
Studiesexamining thehypothermiceffectsofperiph-
erally administered MPP+suggest the hypothermia is
not directly mediated through a central CNS mech-
anism, despite the finding that labeled MPTP can
bind in the hypothalamus [44], a primary site of
central temperature regulation [45]. In the periphery,
MPTP is converted to MPP+ by several mechanisms
includingMAO-B[46],mitochondrion-targetedhuman
cytochrome P450 2D6 (CYP2D6) [47] and rat liver
cytochromes P-450IIB1 and P-450IA1 [48]. Once con-
verted to MPP+, this radical can be taken into cells
preferentially through the dopamine transporter (DAT),
although other have suggested alternative methods
for cellular uptake including transport through the
organic cation transporter, known in mouse as Orct3
(Slc22a1) [49]. Once in cells, MPP+ interferes with
NADH-ubiquinone oxidoreductase (complex I) of the
mitochondrial electron transport chain [50, 51] leading
to a reduction in cellular ATP [52], a depletion of cat-
echolaminergic stores [53–55] and increase in cellular
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Fig. 4. Effect of MPTP on purine levels in the substantia nigra. Intraperitoneal administration of 4 injections of 20 mg/kg MPTP spaced 2 hours
apart does not alter adenosine, ADP or AMP levels. Starting 15 minutes after the 2nd injection of MPTP (135 minutes after the first injection),
there is a significant loss of ATP that is maintained until 2 hrs after the last injection, when this purine begins to recover to baseline levels. The
MPTP-induced changes in ATP are not affected by the addition of an external heat source. ∗p≤ 0.05 compared to no heat controls; $p≤ 0.05
compared to heat controls.
adenosine [56]; allofwhichmaycontribute to induction
of cell death.
To examine if maintenance of body temperature
affected purine levels in the brain, both at resting and
after MPTP, we used a novel HPLC-ECD detection
method that allows simultaneous detection of adeno-
sine, ATP, ADP and AMP from brain tissue [37]. As
expected, based on the physiological effects of MPTP
on Complex I, we observed a significant drop in ATP
starting 135 minutes after the initial administration of
MPTP. The timing of this slightly slower than that
reported by Chan et al. [57] who reported a significant
20% drop in ATP in the striatum and ventral mesen-
cephalon within 6 minutes, although they did give a
dose 2x that of this study. We also find a greater loss
of ATP than previously reported (approximately 48%
compared to 20%), which could be due to the effects of
the multiple adminstrations of MPTP versus that of a
single injection; further supported by our observation
that ATP levels start to recover within 2 hours of the
last injection of MPTP.
Like cellular ATP, we also noted a drop in striatal
DA occurring 2–4 hours after the start of MPTP admin-
istration. This significant loss occurs at the same time
as we observed a significant loss of ATP.
Loss of cellular energy (ATP) can reduce the ani-
mal’s ability to maintain its cellular metabolism and
maintain temperature homeostasis as well as maintain
critical function of organ systems [58]. The main-
tenance of core body temperature occurs through
a balance between heat generation and heat loss.
When heat loss is greater than generation, hypothermia
occurs. Since generation of body heat requires energy
consumption, including induction of shivering and
active vasoconstriction, loss of ATP would be expected
to allow for a hypothermic response. Given that there
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Fig. 5. Effect of MPTP on dopamine DOPAC and HVA levels in striatum.. Intraperitoneal administration of 4 injections of 20 mg/kg MPTP
spaced 2 hours apart induces a significant loss of dopamine 15 minutes after the 2nd injection of 20 mg/kg MPTP (135 minutes after the first
injection) that is progressive after each subsequent injection. There is a reduction of DOPAC that is seen 15 minutes after the third injection (195
minutes after the first injection). No change in HVA is seen in animals not provided an external heat source, although a small but significant
change is seen in animals in heated cages starting 15 minutes after the 4th injection of MPTP (495 minutes after the first injection). 15 minutes
after the 4th injection of MPTP, animals in heated cages show an increase in dopamine turnover. ∗p≤ 0.05 compared to no heat controls;
$p≤ 0.05 compared to heat controls; #∗p≤ 0.05 non heated cages compared to heated cages.
appears to be little-to-no expression in skeletal muscle
of the dopamine transporter and organic cation trans-
porter 3 [59] or extraneuronal monoamine transporter
[60], the effects of peripheral MPTP administration on
muscle may be an indirect effects of changes occur-
ring in the CNS. This is supported by studies that have
shown that CNS injection of the dopamine antagonist,
haloperidol [61], can induce a marked hypothermia.
One major observation we made in this study, and
have noted in other experiments in our lab (Smeyne,
unpublished observations) was that mice that received
MPTP but were not provided with an external heat
source did not survive more than 24 hours after the
completion of the MPTP injection regimen. As noted
earlier, C57BL/6J mice in this study had a ∼31%
loss of body temperature that ultimately matched the
animal’s cage temperature, and this temperature was
slightly greater than the reported Fatal Hypothermic
Temperature (FHT) of mice [31]. When access was
given to an external heat source, these animals still
became hypothermic, but the total body temperature
loss was only ∼17% of its initial core temperature and
significantly above the FHT. Since only 20% of these
mice died, it appears that this 17% loss in body tem-
perature was sufficiently tolerated by the C57BL/6J
mice.
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In conclusion, we examined the effect of MPTP
and paraquat on core body temperature in C57BL/6J
mice. Although both of these chemicals have been
reported to induce experimental parkinsonism, only
MPTP induced a hypothermic response that without
external heat support proved fatal. Since MPTP and
PQ work via different cellular mechanisms, it is likely
that the peripheral hypothermia that is only seen in
mice given MPTP is due its blockade of Complex I
and subsequent downstream effects, while PQ, which
affects cells via a direct lipid redox mechanism [62],
does not affect cellular metabolism and thus has little
effect core temperature.
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